Mechanism of action and limited cross-resistance of new lipopeptide MX-2401

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2743-2754

  Rubinchik, E ^a   Schneider, T ^b   Elliott, M ^c   Scott, W R P ^c   Pan, J ^c   Anklin, C ^d   Yang, H ^a,c   Dugourd, D ^a,e   Muller A ^b   Gries, K ^b   Straus, S K ^c   Sahl, H G ^b   Hancock, R E W ^c  

^a BioWest Therapeutics Inc   (Canada)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRUKER BIOSPIN CORPORATION   (United States)

^e BD Diagnostics Infectious Disease   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 PALMITOYL 2 OLEOYL SN GLYCERO 3 PHOSPHO (1' RAC GLYCEROL); 2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; AMFOMYCIN; CALCEIN; CARRIER PROTEIN; DAPTOMYCIN; LIPOTEICHOIC ACID; MX 2401; PEPTIDOGLYCAN; UNCLASSIFIED DRUG; UNDECAPRENYLPHOSPHATE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE FUSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; LIPOPEPTIDES; STAPHYLOCOCCUS; URIDINE DIPHOSPHATE N-ACETYLMURAMIC ACID;

EID: 79956328681     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00170-11     Document Type: Article

References (50)

1. Baltz, R. H., V. Miao, and S. K. Wrigley. 2005. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat. Prod. Rep. 22:717-741.
2. Berendsen, H. J. C., J. P. M. Postma, W. F. van Gunsteren, A. Dinola, and J. R. Haak. 1984. Molecular-dynamics with coupling to an external bath. J. Chem. Phys. 81:3684-3690.
3. Berney, M., F. Hammes, F. Bosshard, H. U. Weilenmann, and T. Egli. 2007. Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry. Appl. Environ. Microbiol. 73:3283-3290.
4. Braunschweiler, L., and R. R. Ernst. 1983. Coherence transfer by isotropic mixing: application to proton correlation spectroscopy. J. Magn. Reson. 53:521-528.
5. Brötz, H., et al. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30:317-327.
6. Brown, S., Y. H. Zhang, and S. Walker. 2008. Revised pathway proposed for Staphylococcus aureus wall teichoic acid biosynthesis based on in vitro reconstitution of the intracellular steps. Chem. Biol. 15:12-21.
7. Bunkóczi, G., L. Vertesy, and G. M. Sheldrick. 2005. Structure of the lipopeptide antibiotic tsushimycin. Acta Crystallogr. D Biol. Crystallogr. 61:1160-1164.
8. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 7th ed. CLSI document M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Craig, W. A., D. Andes, and T. Satmstad. 2010. In vivo pharmacodynamics of a new lipopeptide MX-2401. Antimicrob. Agents Chemother. 54:5092-5098.
10. Dai, D., and E. E. Ishiguro. 1988. murH, a new genetic locus in Escherichia coli involved in cell-wall peptidoglycan biosynthesis. J. Bacteriol. 170:2197-2201.
11. Debono, M., et al. 1988. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. 41:1093-1105.
12. Dugourd, D., et al. 2006. In vitro characterization of MX-2401 - a novel amphomycin derivative active against gram positive bacteria, abstr. F1-1879. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother.
13. Dugourd, D., H. Yang, and E. Rubinchik. 2009. MX-2401: a novel lipopeptide active in the presence of lung surfactant and in Streptococcus pneumoniae bronchial-alveolar pneumonia model, abstr. F1-2026. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
14. Ho, S. W., et al. 2008. Effect of divalent cations on the structure of the antibiotic daptomycin. Eur. Biophys. J. 37:421-433.
15. Hoban, D. J., B. Weshnoweski, R. Vashisht, G. G. Zhanel, and D. Dugourd. In vitro activity of MX-2401, a novel lipopeptide against multi-drug resistant (MDR) Staphylococcus aureus (SA), abstr. F1-363. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.
16. Hwang, T. L., and A. J. Shaka. 1995. Water suppression that works - excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J. Magn. Reson. Ser. A 112:275-279.
17. Jeener, J., B. H. Meier, P. Bachmann, and R. R. Ernst. 1979. Investigation of exchange processes by two-dimensional NMR spectroscopy. J. Chem. Phys. 71:4546-4553.
18. Jung, D., J. P. Powers, S. K. Straus, and R. E. W. Hancock. 2008. Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes. Chem. Phys. Lipids 154:120-128.
19. Jung, D., A. Rozek, M. Okon, and R. E. W. Hancock. 2004. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 11:949-957.
20. Kang, M. S., J. P. Spencer, and A. D. Elbein. 1978. Amphomycin inhibition of mannose and GlcNAc incorporation into lipid-linked saccharides. J. Biol. Chem. 253:8860-8866.
21. Kohlrausch, U., and J. V. Holtje. 1991. Analysis of murein and murein precursors during antibiotic-induced lysis of Escherichia coli. J. Bacteriol. 173:3425-3431.
22. Marion, D., and K. Wuthrich. 1983. Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 113:967-974.
23. Muraih, J. K., A. Pearson, J. Silverman, and M. Palmer. 2011. Oligomerization of daptomycin on membranes. Biochim. Biophys. Acta 1808:1154-1160.
24. Nanzer, A. P., W. F. van Gunsteren, and A. E. Torda. 1995. Parametrization of time-averaged distance restraints in Md simulations. J. Biomol. NMR 6:313-320.
25. Pasetka, C. J., D. J. Erfle, D. R. Cameron, J. J. Clement, and E. Rubinchik. 2010. Novel antimicrobial lipopeptides with long in vivo half-lives. Int. J. Antimicrob. Agents 35:182-185.
26. Pettersen, E. F., et al. 2004. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
27. Ryckaert, J. P., G. Ciccotti, and H. J. C. Berendsen. 1977. Numericalintegration of Cartesian equations of motion of a system with constraints - molecular-dynamics of N-alkanes. J. Comput. Phys. 23:327-341.
28. Schneider, T., et al. 2009. The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob. Agents Chemother. 53:1610-1618.
29. Schneider, T., et al. 2010. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328:1168-1172.
30. Schneider, T., et al. 2004. In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus. Mol. Microbiol. 53:675-685. (Pubitemid 38998184)
31. Schneider, T., and H. G. Sahl. 2010. An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway. Int. J. Med. Microbiol. 300:161-169.
32. Scott, W. R. P., S. B. Baek, D. Jung, R. E. W. Hancock, and S. K. Straus. 2007. NMR structural studies of the antibiotic lipopeptide daptomycin in DHPC micelles. Biochim. Biophys. Acta 1768:3116-3126.
33. Scott, W. R. P., et al. 1999. The GROMOS biomolecular simulation program package. J. Phys. Chem. A 103:3596-3607.
34. Scott, W. R., et al. 2006. Characterization of de novo four-helix bundles by molecular dynamics simulations. Proteins 64:719-729. (Pubitemid 44100737)
35. Silverman, J. A., L. I. Mortin, A. D. G. VanPraagh, T. Li, and J. Alder. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191:2149-2152.
36. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
37. Singh, M. P. 2006. Rapid test for distinguishing membrane-active antibacterial agents. J. Microbiol. Methods 67:125-130.
38. Straus, S. K., and R. E. W. Hancock. 2006. Mode of action of the new antibiotic for Gram-positive pathogens, daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223.
39. Tanaka, H., Y. Iwai, R. Oiwa, S. Shinohara, S. Shimizu, T. Oka, and S. Omura. 1977. Studies on bacterial cell wall inhibitors. II. Inhibition of peptidoglycan synthesis in vivo and in vitro by amphomycin. Biochim. Biophys. Acta 497:633-640.
40. Tanaka, H., R. Oiwa, S. Matsukura, J. Inokoshi, and S. Omura. 1982. Studies on bacterial cell wall inhibitors. X. Properties of phospho-N- acetylmuramoyl pentapeptidetransferase in peptidoglycan synthesis of Bacillus megaterium and its inhibition by amphomycin. J. Antibiot. 35:1216-1221. (Pubitemid 13256019)
41. Tanaka, H., R. Oiwa, S. Matsukura, and S. Omura. 1979. Amphomycin inhibits phospho-N-acetylmuramyl-pentapeptide translocase in peptidoglycan synthesis of Bacillus. Biochem. Biophys. Res. Commun. 86:902-908.
42. Tironi, I. G., R. Sperb, P. E. Smith, and W. F. van Gunsteren. 1995. A generalized reaction field method for molecular-dynamics simulations. J. Chem. Phys. 102:5451-5459.
43. Torda, A. E., R. M. Scheek, and W. F. van Gunsteren. 1989. Time-dependent distance restraints in molecular-dynamics simulations. Chem. Phys. Lett. 157:289-294.
44. van Gunsteren, W. F., et al. 1996. Biomolecular simulation: the GROMOS96 manual and user guide. VdF, Hochschulverlag AG an der ETH Zurich BIOMOS b.v., Zurich, Switzerland.
45. van Heijenoort, J. 2001. Formation of the glycan chains in the synthesis of bacterial peptidoglycan. Glycobiology 11:25R-36R.
46. Vértesy, L., et al. 2000. Friulimicins: novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. J. Antibiot. 53:816-827.
47. Wiegand, I., K. K. Hilpert, and R. E. W. Hancock. 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3:163-175.
48. Wong, K. K., et al. 1998. Engineering a cell-free murein biosynthetic pathway: combinatorial enzymology in drug discovery. J. Am. Chem. Soc. 120:13527-13528.
49. Zhang, L., A. Rozek, and R. E. W. Hancock. 2001. Interaction of cationic antimicrobial peptides with model membranes. J. Biol. Chem. 276:35714-35722.
50. Zhou, G.-P., and A. F. Troy II. 2005. NMR study of the preferred membrane orientation of polyisoprenols (Dolichol) and the impact of their complex with polyisoprenyl recognition sequence peptides on membrane structure. Glycobiology 15:347-359.